Open Access

Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp-PLA2 ): a review

Lipids in Health and Disease201110:170

DOI: 10.1186/1476-511X-10-170

Received: 26 July 2011

Accepted: 28 September 2011

Published: 28 September 2011

Abstract

The association of cardiovascular events with Lp-PLA2 has been studied continuously today. The enzyme has been strongly associated with several cardiovascular risk markers and events. Its discovery was directly related to the hydrolysis of the platelet-activating factor and oxidized phospholipids, which are considered protective functions. However, the hydrolysis of bioactive lipids generates lysophospholipids, compounds that have a pro-inflammatory function. Therefore, the evaluation of the distribution of Lp-PLA2 in the lipid fractions emphasized the dual role of the enzyme in the inflammatory process, since the HDL-Lp-PLA2 enzyme contributes to the reduction of atherosclerosis, while LDL-Lp-PLA2 stimulates this process. Recently, it has been verified that diet components and drugs can influence the enzyme activity and concentration. Thus, the effects of these treatments on Lp-PLA2 may represent a new kind of prevention of cardiovascular disease. Therefore, the association of the enzyme with the traditional assessment of cardiovascular risk may help to predict more accurately these diseases.

Keywords

Lp-PLA2 Cardiovascular risk antioxidant pro-inflammatory

1. Introduction

The physiopathology of cardiovascular disease (CVD) is marked by the presence of atherosclerosis that involves endothelial dysfunction, inflammation, oxidative stress, insulin resistance and dyslipidemia.

Even considering the early diagnosis and the new variety of treatments for CVD, the American College of Cardiology still predicts that there will be 25 million cases only in USA until the end of 2050 [1]. Furthermore, given the current importance of CVD, thanks to its high worldwide prevalence that accounts for nearly 30% of the global deaths [2], the monitoring of the new biomarkers and risk factors represents an important focus of new researches.

In this context, lipoprotein-associated phospholipase A2 (Lp-PLA2 ) represents a potential cardiovascular risk marker, given its correlations with coronary disease and stroke [37]. Initially, Lp-PLA2 was recognized by its action on hydrolyzing platelet-activating factor (PAF); such characteristic has assigned to it the first name platelet-activating factor acetylhydrolase (PAF-AH) [8].

Despite the other important reviews of Lp-PLA2[911], the question of whether high activity of Lp-PLA2 is a causal event or a result of atherosclerosis remains open. Therefore, the main goal of this review is to show the antioxidant and inflammatory role of Lp-PLA2 and its connection with atherosclerosis, aiming to contribute to the discussions of atherogenic or anti-atherogenic role of Lp-PLA2 . We also discuss possible mechanisms of modulation of Lp-PLA2 .

2. Biochemistry and structural aspects

A brief biological background is necessary to comprehend mechanisms enrolling Lp-PLA2 and atherosclerosis. Platelet-activating factor (PAF) is an active phospholipid related to many pathologic and physiologic reactions [12]. The PAF is formed through two reactions (Figure 1). Firstly, the cytosolic phospholipase A2 (cPLA2 ) acts on membrane phospholipids producing lysophospholipids; then, the lysophospholipids are modified by PAF acetyltransferase, resulting in the formation of PAF [13]. Thus, PAF concentration is modulated by Lp-PLA2 activity [13, 14].
https://static-content.springer.com/image/art%3A10.1186%2F1476-511X-10-170/MediaObjects/12944_2011_Article_569_Fig1_HTML.jpg
Figure 1

Role of Lp-PLA 2 on the generation of lysophospholipids.

Lp-PLA2 was discovered on 1980 and it was classified as a Ca2+-independent PLA2[8], produced by a wide range of inflammatory and non-inflammatory cells [1517]. It is considered a member of phospholipases family (PLA2 ), although exhibits different properties when compared to other PLA2[18]. In addition, while Lp-PLA2 is specific for the breakdown of PAF and oxidized fatty acid residues, PLA2 is specific for phospholipids containing two long chain acyl groups [1821].

Another feature of Lp-PLA2 is that it shows different isoforms, though the more common types are distributed in intracellular [22] and extracellular compartment [8]. Intracellular Lp-PLA2 shows two variables, I and II [23], while brain tissue exhibits a subtype named Lp-PLA2 -Ib [24]. The Lp-PLA2 type II consists of a 40-KDa polypeptide chain, and has been associated with antioxidant properties [25]. The extracellular Lp-PLA2 , identified as plasma form, circulates in association primarily with LDL (80-85%) and on minor portion with HDL (15-20%), having its activity strongly correlated with the cholesterol concentrations [26, 27]. Lp-PLA2 has been extracted from human plasma and erythrocytes, bovine brain, liver and seminal plasma, guinea pig peritoneal fluid and plasma, mouse plasma and platelets, cultured rat Kupffer cell- and hepatocyte-conditioned media, rat bile and the parasite Nippostrongylus brasiliensis[28]. On the same hand, it was verified that the different isoforms of Lp-PLA2 define distinct activities for the enzyme [23, 29, 30].

3. Antioxidant role of Lp-PLA2

The oxidative stress is closely associated with inflammation and bioactive lipid formation. These bioactive lipids, such as PAF, PAF-like substances, and oxidized phospholipids, have been identified in atherosclerotic plaque [31]. PAF-like products are formed when the phospholipids of the cellular membrane suffers oxidative damage, resulting in compounds that have structures with shorter peroxidized residues at their second carbon and that mimic the action of PAF [32].

In presence of oxidized phospholipids, Lp-PLA2 removes these fragments acting as an antioxidant. Matsuzawa et al.[33], suggested that the over expression of Lp-PLA2 protects the cells of reactive oxygen species (ROS)-induced apoptosis through oxidized phospholipids hydrolysis.

In addition, oxidized LDL and LDL(-) are known to be important factors on the atherosclerosis initiation and development [3436]. Heery et al.[37] demonstrated that the formation of oxidized phospholipids in LDL stimulates Lp-PLA2 activity. It is most likely that the Lp-PLA2 hydrolysis of the lipids present in this particle represents an important antiatherogenic role. In this context, Watson et al.[38] showed that the Lp-PLA2 , hydrolyzing oxidized phospholipids, minimizes the generation of highly oxidized LDL, increasing the minimally oxidized LDL content. Subsequently, Benitez et al.[39] found that the major portion of Lp-PLA2 was associated with LDL(-) in detriment to LDL(+), suggesting that the release of chemotactic induced by LDL(-) could be a consequence of the high Lp-PLA2 activity. Indeed, LDL(-) can be generated by Lp-PLA2 , although the origin of this sub-group of LDL could to be also compatible with oxidative reaction and other mechanisms such as non enzymatic glycosylation, changes on Apo E (apolipoprotein E) and Apo CII (apolipoprotein CII), non esterified fat acids (NEFAS) enrichment or cross linking with hemoglobin [40].

Lourida et al.[41] showed that Lp-PLA2 activity is important for reducing the immunogenicity of oxLDL, a phenomenon that can be attributed to the decreasing of oxidized phospholipids in patients with coronary artery disease and healthy ones. More recently, Noto et al.[42] showed in animals that Lp-PLA2 protects lipoproteins from oxidation, producing less proatherogenic lipoproteins and preserving HDL functions. In this direction, Bazan [43] proposed that recombinant Lp-PLA2 could be a potential tool directed to antiatherogenic therapy.

4. Inflammatory action of Lp-PLA2

Despite the antioxidant potential described above, the association of Lp-PLA2 with inflammatory reactions represents the majority of the studies in literature in the last years.

When Lp-PLA2 hydrolyzes bioactive lipids, reducing their biological activity, the most generated metabolites are the lysophospholipids. These lipids are involved with atherosclerotic process and show a deleterious role of Lp-PLA2 , contributing to the inflammatory response against oxidized lipoproteins [39, 44, 45]. These compounds generated by phospholipases A2 during cell activation, injury, or apoptosis, are known to affect the function of neutrophils and of a diversity of cell types [46], and can be also produced by phospholipase A1 and by the action of lecithin-cholesterol acyltransferase (LCAT) or endothelial lipase. There are many different lysophospholipids, but the main product of Lp-PLA2 action is lysophosphatidylcholine [47]; these metabolic processes occur in physiological conditions.

Furthermore, lysophospholipids from apoptotic cells contribute to attract monocytic cells and primary macrophages [48, 49]. In this context, Steinbrecher & Pritchard [45] showed that oxLDL, on the presence of phenylmethanesulphonylfluoride (PMSF), an inhibitor of Lp-PLA2 , has lower values of lysophospholipids. In this fashion, Muller et al.[50] proposed that lysophosphatidylcholine represents a biomarker of the intensity of the reactive oxygen species production at the inflammatory site. Accordingly, Lavi et al.[51] found that patients with early coronary atherosclerosis had higher lysophosphatidylcholine when compared with control subjects. This profile was confirmed by Herrmann et al.[52], who showed that carotid artery plaques of patients with cardiac events presented higher Lp-PLA2 , lysophospholipids, macrophage and collagen content when compared to patients without events.

Studying the effects of oxLDL, Kuniyasu et al.[53] demonstrated that oxLDL, and particularly, the lysophosphatidylcholine present in this particle, enhances the plasminogen activator inhibitor-1 expression. Vickers et al.[54] demonstrated also that lysophosphatidylcholine can contribute to calcify vascular cells on the atherosclerotic plaque, through up-regulation of osteogenic genes and proteins. Hence, many events present in atherosclerotic process involve directly Lp-PLA2 or its products.

Figure 2 summarizes the possible atherogenic mechanisms involving Lp-PLA2 . In this context, there can be an individual with dyslipidemia, obesity, hypertension, insulin resistance and oxidative stress, and therefore, highly prone to atherosclerosis. These factors contribute initially to the endothelial dysfunction, characterized by the expression of more adhesion molecules and by larger spaces between endothelial cells. Thus, the LDL, macrophages and T lymphocytes can transmigrate more easily to arterial intima. This LDL particle shows a phenotype more atherogenic, being dense and small, characteristics that make it more susceptible to oxidation. In this site, the reduced content of antioxidants favors the high production of free radicals, and consequently oxidative modifications of LDL. Thus, the Lp-PLA2 will be activated by oxidized phospholipids present in OxLDL.
https://static-content.springer.com/image/art%3A10.1186%2F1476-511X-10-170/MediaObjects/12944_2011_Article_569_Fig2_HTML.jpg
Figure 2

Possible actions of Lp-PLA 2 in the atherosclerotic process.

The enzyme minimizes modifications of OxLDL, hydrolyzing its oxidized phospholipids; this may be interpreted as an antioxidant action. However, during this process, there are produced high contents of lysophospholipids and oxidized non esterified fat acids (OxNEFAS) that promote adhesion molecules expression and attract macrophages to the arterial intima. The OxLDL, lysophospholipids and OxNEFAS also stimulates cytokines production, like TNF-α and IL-6, which increase the inflammatory profile in the region of the plate. The activated macrophages, through scavenger receptors, phagocyte OxLDL, gradually turning up in foam cells. The muscle cells are also attracted, and migrate to the intima, where they produce collagen, elastin and elastases, involving and stabilizing the lipid plaque. Subsequently, the macrophages become apoptotic, as well as the muscle cells, causing released of lipids in the plaque. In this process, the presence of OxLDL, as well as lysophospholipids and OxNEFAS produced by Lp-PLA2, is always stimulating the growth of the plaque; these are factors that can be decisive to plaque rupture susceptibility that can culminate in a cardiovascular event.

5. Lp-PLA2 and Cardiometabolic Risk

Taking into account the mechanisms described, Lp-PLA2 could influence the cardiometabolic risk; the Figure 3 expresses the two main possibilities for action of the enzyme in cardiovascular disease context; the antioxidant action, where these hydrolysis reduce the oxidized phospholipids in plasma and the oxLDL contributing to generation of LDL(-); the inflammatory action, where the hydrolysis of PAF, PAF-like products or oxidized phospholipids generate lysophospholipids that stimulate inflammation, so the atherogenic process is stimulated.
https://static-content.springer.com/image/art%3A10.1186%2F1476-511X-10-170/MediaObjects/12944_2011_Article_569_Fig3_HTML.jpg
Figure 3

Lp-PLA 2 action on cardiovascular disease.

According to Campo et al.[55], Lp-PLA2 activity was significantly associated with LDL-cholesterol in hypercholesterolemic patients. As a matter of fact, dyslipidemia promotes an increase in plasma Lp-PLA2 activity and alters the enzyme distribution between apo B- and apo AI-containing lipoproteins, as observed by Tsimihodimos et al.[56]. The role of LDL-associated Lp-PLA2 remains controversial, possibly because of the difficulty in analyzing the actions of the enzyme in the dense LDL particle [57].

On the other hand, studies also have showed that the enzyme activity associated with HDL particles can play an antiatherogenic action. Theilmeier et al.[58] demonstrated by in vitro and in vivo models that HDL-Lp-PLA2 (HDL-Lipoprotein-associated phospholipase A2 ) activity was linked to reduction of endothelial adhesiveness and of macrophage recruitment to lesion prone sites. Afterwards, the same group demonstrated that atorvastatin induced the increase of HDL-Lp-PLA2 activity and the reduction of LDL-Lp-PLA2 (LDL-Lipoprotein-associated phospholipase A2 ) activity [56].

Papavasiliou et al.[59], investigating chronic kidney disease patients, found an increase in plasma Lp-PLA2 activity and a reduction of the ratio of HDL-Lp-PLA2 to plasma when compared to controls. In the same way, Rizos et al.[26] demonstrated that patients with metabolic syndrome have higher Lp-PLA2 activity than controls. Nevertheless, the Lp-PLA2 content in HDL was lower; these results were confirmed by Lagos et al.[60], who observed that the HDL-Lp-PLA2 activity was lower in patients with metabolic syndrome. Okamura et al.[31] suggested that even the Lp-PLA2 having an important function in atherogenesis, its association with HDL plays the opposite role, as observed by high LDL-Lp-PLA2 to HDL-Lp-PLA2 ratio in patients with atrial fibrillation.

In this fashion, Noto et al.[61] showed that diabetic patients with metabolic syndrome have significantly higher Lp-PLA2 activity than those without this disease, reflecting its importance to metabolic risk. Following up, in a cohort with 299 subjects, Allison et al.[62] demonstrated that an increment of one standard deviation in Lp-PLA2 activity was associated with a higher risk of CVD in five years, but not with mortality. Kiechl et al.[63], in a prospective study, demonstrated that oxidized phospholipids/apo B ratio predicted the cardiovascular risk, being the Lp-PLA2 activity an amplifier of this risk.

Accordingly, Sabatine et al.[4] observed that an elevated level of Lp-PLA2 is a predictor of adverse cardiovascular outcomes, independently of the traditional clinical risk factors in patients with stable coronary artery disease. Persson et al.[64] observed that this enzyme was strongly correlated with lipid fractions and the degree of carotid artery atherosclerosis; this study showed that the association with cardiovascular risk is stronger for activity than for mass, reinforcing the impact of activity in atherogenesis [64].

In a prospective population-based survey, which occurred between 1990 and 2005, it was verified that Lp-PLA2 was higher in subjects with incidence of CVD [5]. In the same year, Jenny et al.[65] showed that subjects with heart failure have the elevation of Lp-PLA2 levels associated with an increase in the mortality risk. It was detected also that subjects aged > 65 years presented an association between the Lp-PLA2 and myocardial infarction [65]. An increasing risk of major adverse cardiac events associated with elevated Lp-PLA2 was also observed in community-based cohort of patients with acute coronary syndrome [6].

More recently, the Lp-PLA2 Studies Collaboration, analyzing 32 prospective studies, confirmed that the enzyme activity and mass were related to proatherogenic lipids and vascular risk [66]. The study showed also that the association of the enzyme activity with lipid markers is stronger than the association with mass [66]. Recently, the authors of this review verified that the Lp-PLA2 activity in adolescents is positively associated with total cholesterol, LDL-C, insulin, glucose, HOMA-IR, Apo B (apolipoprotein B)/Apo AI (apolipoprotein AI) ratio and negatively related to HDL size.

In contrast with the studies above, Tsironis et al.[67] showed that patients with coronary disease exhibit reduced LDL-Lp-PLA2 mass and catalytic efficiency, suggesting a diminished ability to degrade pro-inflammatory phospholipids.

Therefore, it is probably that Lp-PLA2 shows a dual action, directly dependent on its association with LDL (proatherogenic) or HDL (antiatherogenic). Table 1 summarizes the antioxidant, inflammatory and neutral links between Lp-PLA2 and cardiometabolic risk.
Table 1

Potential action of the Lp-PLA2 , according to studies with distinct design.

Study design

Action

Reference

Experimental

Cells ROS protection.

[33]

Experimental

↓ bioactivity phospholipids in oxLDL

[37]

Experimental

↓ oxidized phospholipids in mildly oxLDL

[38]

Case/Control

≈ Oxidized phospholipids and anti-Lp-PLA2

[41]

Case/Control

↓ HDL oxidation, foam cell and autoantibodies titers.

[42]

Case/Control

↓ HDL-Lp-PLA2 activity

[25]

Case/Control

↓ HDL-Lp-PLA2 activity

[60]

Case/Control

↑ LDL-Lp-PLA2 to HDL-Lp-PLA2 ratio

[31]

Case/Control

↓ HDL-Lp-PLA2 and ↑ of LDL-Lp-PLA2

[56]

Case/Control

≈ Lp-PLA2 activity

[55]

Case/Control

↑ Lp-PLA2 activity

[61]

Cohort

↑ Lp-PLA2 activity in CHD mortality

[62]

Case/Control

↑ Lp-PLA2 activity

[63]

Cohort

Predictor of cardiovascular outcomes

[4]

Cohort

Lp-PLA2 correlated with cardiovascular risk factors

[64]

Cohort

Lp-PLA2 activity associated with MS and CVD

[5]

Cohort

Lp-PLA2 mass and activity associated with CVD

[65]

Cohort

↑ Lp-PLA2 activity associated with CVD

[6]

Meta-analysis

Lp-PLA2 mass and activity associated vascular risk

[66]

CVD: Cardiovascular Disease; CHD: Coronary Heart Disease; PAD: Peripheral Arterial Disease; ROS: Reactive Oxygen Species, MS: Metabolic Syndrome

6. Modulation of Lp-PLA2

Studies focused on Lp-PLA2 modulation are little explored in literature, despite of its possible manipulation. Regarding that Lp-PLA2 is associated with cholesterol and oxidized lipids in LDL and HDL, it is probable that drugs and environment factors, capable of modulating the lipid metabolism, may change the mass and the activity of this enzyme.

Gerra et al.[68] showed that lovastatin was responsible for the simultaneous decrease of LDL-C level and Lp-PLA2 activity. Similary, Tsimihodimos et al.[56] found reduced Lp-PLA2 activity in plasma of hypercholesterolemic patients under atorvastatin therapy, with a reduction in LDL-Lp-PLA2 activity; in contrast, there was no modification in HDL-Lp-PLA2 activity. The same authors, in an investigation of the effect of fenofibrate on hypercholesterolemic patients, observed a reduction in the LDL-Lp-PLA2 activity and an increase of the HDL-Lp-PLA2 activity [69]. Schaefer et al.[70], comparing the effect of atorvastatin with placebo in coronary heart disease patients observed a reduction of Lp-PLA2 under therapy.

Studying the effect of cholesterol feeding and simvastatin treatment on rabbits, Zhang et al.[71] found that the LDL-Lp-PLA2 activity increased with cholesterol feeding and decreased after the treatment. In this way, O'Donoghue et al.[72] found that an intensive statin therapy was responsible for 20% of reduction in LDL-Lp-PLA2 , in average. Likewise, Schaefer et al.[70] observed that simvastatin determined a reduction of the Lp-PLA2 mass in 26%.

In the same way, atorvastatin or fenofibrate therapies can increase the ratio of HDL-Lp-PLA2 to plasma Lp-PLA2 (or to LDL-Lp-PLA2 ) [57]. Also, the effect of gemfibrozil was monitored in men with low HDL-C, and it was verified that individuals in highest quartile of Lp-PLA2 showed reduction of cardiovascular events [73]. The use of darapladib (oral Lp-PLA2 inhibitor) by coronary patients caused a reduction of 59% of the enzyme activity after 12 months of treatment; concomitantly, the placebo group presented a significant increase of necrotic core volume when compared to the therapy group [74]. In a complementary study, the combined effect of atorvastatin and darapladib was evaluated in patients with coronary heart disease in the course of 12 weeks; the individuals under darapladib showed a reduction of approximately 54% in the Lp-PLA2 activity when compared with controls [75].

Investigating patients under low-fat-diet and orlistat treatment, fenofibrate or both drugs during six months, Filippatos et al.[76] observed a significant reduction of Lp-PLA2 activity in all groups (14%, 22% and 35%, respectively) when compared to basal time. The results suggested the combination of the two treatments as the optimal therapy.

Hence, the direct influence of lipid metabolism on Lp-PLA2 was confirmed by the efficiency of hypocholesterolemic drugs. Nonetheless, a similar profile was not observed in patients under anti-hypertension treatment: Spirou et al.[77] and Rizos et al.[78] verified that anti-hypertensive was not able to change Lp-PLA2 activity.

Despite the positive effect on Lp-PLA2 demonstrated by application of drugs, many studies have also investigated the influence of diet and other environment factors on the enzyme. In this context, Pedersen et al.[79] compared the effects of high (6.6 g), low (2.0 g) and control doses of n-3 polyunsaturated fatty acids in some metabolic parameters; they did not observe any effect on Lp-PLA2 activity. Recently, in a sub-sample (n = 150, follow up = 1 y) of PREDIMED study, the authors of the present work, comparing diets enhanced with a mix of nuts (30 g/d), olive oil (50 g/d) or with low concentration of saturated fat (< 7%), observed a reduction in Lp-PLA2 only in the nuts group [NRTD, personal communication].

The effect of selenium on Lp-PLA2 was recently evaluated [80] on rats, subject to three different diets (control, high fat and high fat enhanced with selenium). The results showed that the Lp-PLA2 levels in control group were lower than the other groups, and that the selenium did not affect this enzyme.

The Nurses' Health Study demonstrated that the replacement of energy from carbohydrates for proteins, as well as the alcohol consumption or use of cholesterol-lowering drugs, were associated with a reduction in the Lp-PLA2 activity. Smoking, overweight, aspirin use, hypercholesterolemia and age were, nevertheless, related to the elevation of Lp-PLA2 activity [81]. In addition, obese and non-diabetic women submitted to a weight reduction program showed a significant reduction in Lp-PLA2 activity, directly associated with VLDL-C [82]. The influence of the nutritional status on Lp-PLA2 activity was also evaluated in adolescents where it was positively associated with body mass index, waist circumference and fat mass percentage [83].

Finally, Chen et al.[84] compared vegetarians with omnivores and observed that vegetarians presented lower Lp-PLA2 activity, with lower total cholesterol and LDL-cholesterol, but with increased chances of higher C-reactive protein.

7. Conclusion

Initially, the discovery of the enzyme Lp-PLA2 was associated with its ability to hydrolyze PAF and phospholipids, what was seen as a protective function. The enzyme acts as an antioxidant in the presence of oxidized phospholipids. Thus, Lp-PLA2 , in this sense, represents an important factor, reducing the oxLDL atherogenicity. Nowadays, however, its association with cardiovascular events is the most outstanding characteristic observed.

In addition, associations with several cardiovascular risk markers were also described in the literature. The enzyme hydrolyzes bioactive lipids, reducing their biological activity; the major metabolites generated in the process are the lysophospholipids. Given these results, the enzyme has been associated with a pro-inflammatory action, explained mainly by the production of these compounds that stimulate the inflammatory process in the region of the atherosclerotic plate.

Focusing on the enzyme antiatherogenic function, several studies have been evaluating the distribution of Lp-PLA2 in the lipid fractions. Surprisingly, the HDL-Lp-PLA2 enzyme has proven beneficial results to the atherosclerotic process. In the same sense, LDL-Lp-PLA2 is linked to higher cardiovascular risk. Drugs and diet components that alter the lipid profile, the insulin resistance and the inflammatory markers also affect the enzyme activity and its concentration. Possibly, the effects of these components on the Lp-PLA2 activity, according to the lipid fraction, represent a new kind of prevention of CVD.

The traditional assessment of cardiovascular risk is based on lipid profile, inflammation and body composition. Since the control of these variables seeks to reduce cardiovascular events and this enzyme is strongly related to them, it is probable that the monitoring of its activity and its distribution on lipoproteins will predict better the cardiovascular risk.

List of abbreviations

Apo AI: 

Apolipoprotein AI

Apo B: 

Apolipoprotein B

Apo CII: 

Apolipoprotein CII

Apo E: 

Apolipoprotein E

cPLA2

Cytosolic phospholipase A2

CVD: 

Cardiovascular disease

HDL-C: 

High density lipoprotein cholesterol

HDL-Lp-PLA2

HDL-Lipoprotein-associated phospholipase A2

LCAT: 

Lecithin-cholesterol acyltransferase

LDL(-): 

Electronegative low-density lipoprotein

LDL-C: 

Low density lipoprotein cholesterol

NEFAs: 

Non esterified fat acids

oxLDL: 

Oxidized low-density lipoprotein

OxNEFAS: 

Oxidized non esterified fat acids

PAF: 

Platelet-activating factor

PAF-AH: 

Platelet-activating factor acetylhydrolase

PAF-like: 

Platelet-activating factor like

PLA2

Phospholipases family

PMSF: 

Phenylmethanesulphonylfluoride

ROS: 

Reactive oxygen species

VLDL-C: 

Very low density lipoprotein cholesterol.

Declarations

Acknowledgements

This study was supported by FAPESP (07/51664-5; 07/52123-8) and CNPQ (474112/07-1). The authors acknowledge Dr Silas Luiz de Carvalho, professor at UNIFESP, whose suggestions contributed to improve the quality of the final version of the manuscript.

Authors’ Affiliations

(1)
Departamento de Nutrição, Faculdade de Saúde Pública, Universidade de São Paulo

References

  1. Foot DK, Lewis RP, Pearson TA, Beller GA: Demographics and cardiology, 1950-2050. J Am Coll Cardiol. 2000, 35: 1067-1081. 10.1016/S0735-1097(00)00561-1View ArticlePubMed
  2. World Health Organization : Global health risks: mortality and burden of disease attributable to selected major risks. Accessed January 10, 2011, http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf
  3. O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald E: Lipoprotein-associated phospholipase a2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the prove it-timi 22 (pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction) trial. Circulation. 2006, 113: 1745-1752. 10.1161/CIRCULATIONAHA.105.612630View ArticlePubMed
  4. Sabatine MS, Morrow DA, O'Donoghue M, Jablonksi KA, Rice MM, Solomon S, Rosenberg Y, Domanski MJ, Hsia J: Prognostic Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease. Arterioscler Thromb Vasc. 2007, 27: 2463-2469. 10.1161/ATVBAHA.107.151670.View Article
  5. Tsimikas S, Willeit J, Knoflach M, Mayr M, Egger G, Notdurfter M, Witztum JL, Wiedermann CJ, Xu Q, Kiechl S: Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur Heart J. 2009, 30: 107-15.View ArticlePubMed
  6. Li N, Li S, Yu C, Gu S: Plasma Lp-PLA2 in acute coronary syndrome: association with major adverse cardiac events in a community-based cohort. Postgrad Med. 2010, 122: 200-205. 10.3810/pgm.2010.07.2187View ArticlePubMed
  7. Iribarren C: Lipoprotein-Associated Phospholipase A2 and C-Reactive protein for Measurement of Inflammatory Risk: Independent or Complementary?. Curr Cardio Risk Rep. 2010, 4: 57-67. 10.1007/s12170-009-0073-0.View Article
  8. Farr RS, Cox CP, Wardlow ML, Jorgensen R: Preliminary studies of an acid-labile factor (ALF) in human sera that inactivates plateletactivating factor (PAF). Clinical Immunology and Immunopathology. 1980, 15: 318-30. 10.1016/0090-1229(80)90044-6View ArticlePubMed
  9. Corson MA, Jones PH, Davidson MH: Review of the Evidence for the clinical Utility of Lipoprotein-Associated Phospholipase A2 as a Cardiovascular Risk Marker. Am J Cardiol. 2008, 101 (suppl): 41F-50F.View ArticlePubMed
  10. Zalewski A, Macphee C: Role of Lipoprotein-Associated Phospholipase A2 in Atherosclerosis Biology, Epidemiology, and Possible Therapeutic Target. Arterioscler Thromb Vasc Biol. 2005, 25: 923-931. 10.1161/01.ATV.0000160551.21962.a7View ArticlePubMed
  11. Epps KC, Wilensky RL: Lp-PLA2 - a novel risk factor for high-risk coronary and carotid artery disease. J InternMed. 2011, 269: 94-106.
  12. O'Flaherty JT, Wykle RL: Biology and biochemistry of platelet-activating factor. Clin Rev Allergy. 1983, 1: 353-367.PubMed
  13. Macmanus LM, Pinckard RN: PAF, aputative mediator of oral inflammation. Crit Rev Oral Biol Med. 2000, 11 (2): 240-258. 10.1177/10454411000110020701View Article
  14. Chen J, Yang L, Foulks JM, Weyrich AS, Zimmerman GA, Marathe GK, McIntyre TM: Intracellular PAF catabolism by PAF acetylhydrolase counteracts continual PAF syntesis. J Lipid Res. 2007, 48 (11): 2365-76. 10.1194/jlr.M700325-JLR200View ArticlePubMed
  15. Karabina SA, Ninio E: Plasma PAF-acetylhydrolase: an unfulfilled promise?. Biochim Biophys Acta. 2006, 1761: 1351-1358.View ArticlePubMed
  16. Venable ME, Zimmerman GA, McIntyre TM, Prescott SM: Platelet-activating factor: a phospholipid autacoids with diverse actions. J Lipid Res. 1993, 34 (5): 691-702.PubMed
  17. Snyder F: Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes. Biochim Biophys Acta. 1995, 1254 (3): 231-249.View ArticlePubMed
  18. Blank ML, Lee T, Fitzgerald V, Snyder F: A specific acetylhydrolase for 1-alkyl-2- acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid). J Biol Chem. 1981, 256: 175-178.PubMed
  19. Dennis EA: The growing phospholipase A2 superfamily of signal transduction enzymes. Trends Biochem Sci. 1997, 22: 1-2. 10.1016/S0968-0004(96)20031-3View ArticlePubMed
  20. Stremler KE, Stafforini DM, Prescott SM, McIntyre TM: Human Plasma Platelet-activating factor aceylhydrolase. J Biol Chem. 1991, 266 (17): 11095-11103.PubMed
  21. Chakraborti S: Phospholipase A2 isoforms: a perspective. Cell Signal. 2003, 15: 637-665. 10.1016/S0898-6568(02)00144-4View ArticlePubMed
  22. Hattori K, Hattori M, Adachi H, Tsujimoto , Arai H, Inoue K: Purification and characterization of platelet-activating factor acetylhdrolase II from bovie liver cytosol. J Biol Chem. 1995, 270 (38): 22308-22313. 10.1074/jbc.270.38.22308View ArticlePubMed
  23. Arai H: Platelet-activating factor acetylhydrolase. Prostaglandins Other Lipid Mediat. 2002, 68-69: 83-94.View ArticlePubMed
  24. Derewenda ZS, Ho YS: PAF-acetylhydrolases. Biochim Biophys Acta. 1999, 1441: 229-236.View ArticlePubMed
  25. Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM: Platelet-activating factor and related lipidmediators. Annu Rev Biochem. 2000, 69: 419-45. 10.1146/annurev.biochem.69.1.419View ArticlePubMed
  26. Rizos E, Tambaki AP, Gazi I, Tselepis AD, Elisaf M: Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids. 2005, 72: 203-209. 10.1016/j.plefa.2004.10.021View ArticlePubMed
  27. Tselepis AD, Chapmam MJ: Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor acetylhydrolase. Atherosclerosis. 2002, 3: 57-68. 10.1016/S1567-5688(02)00045-4View ArticlePubMed
  28. Chroni A, Mavri-Vavayanni M: Characterization of a platelet activating factor acetylhydrolase from rat adipocyte. Life Sci. 2000, 67: 2807-2825. 10.1016/S0024-3205(00)00870-5View ArticlePubMed
  29. Manya H, Aoki J, Kato H, Ishii J, Hino S, Arai H, Inoue K: Biochemical characterization of various catalytic complexes of the brain platelet-activating factor acetylhydrolase. J Biol Chem. 1999, 274 (45): 31827-32. 10.1074/jbc.274.45.31827View ArticlePubMed
  30. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM: Platelet activating factor acetylhydrolases. J Biol Chem. 1997, 272 (29): 17895-8. 10.1074/jbc.272.29.17895View ArticlePubMed
  31. Okamura K, Miura S, Zhang B, Uehara Y, Matsuo K, Kumagai K, Saku K: Ratio of LDL- to HDL-Associated Platelet-Activating Factor Acetylhydrolase may be a Marker of Inflammation in Patients With Paroxysmal Atrial Fibrillation. Circ J. 2007, 71: 214-219. 10.1253/circj.71.214View ArticlePubMed
  32. Tjoelker LW, Stafforini DM: Platelet-activating factor acetylhydrolases in health and disease. Biochim Biophys Acta. 2000, 1488: 102-123.View ArticlePubMed
  33. Matsuzawa A, Hattori K, Aoki J, Arai H, Inoue K: Protection against oxidative stress-induced cell death by intracellular platelet-activating factor-acetylhydrolase II. J Biol Chem. 1997, 272 (51): 32315-20. 10.1074/jbc.272.51.32315View ArticlePubMed
  34. Han J, Hajjar DP, Febbraio M, Nicholson AC: Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36. J Biol Chem. 1997, 272 (34): 21654-9. 10.1074/jbc.272.34.21654View ArticlePubMed
  35. Glass CK, Witztum JL: Atherosclerosis: The Road Ahead. Cell. 2001, 104: 503-516. 10.1016/S0092-8674(01)00238-0View ArticlePubMed
  36. Sánchez-Quesada JL, Benítez S, Ordóñez-Llanos J: Electronegative low-density lipoprotein. Curr Opin Lipidol. 2004, 15: 329-335. 10.1097/00041433-200406000-00014View ArticlePubMed
  37. Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM, Prescott SM: Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest. 1995, 96 (5): 2322-30. 10.1172/JCI118288PubMed CentralView ArticlePubMed
  38. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, McIntyre TM, Du BN, Fogelman AM, Berliner JA: Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest. 1995, 95 (2): 774-82. 10.1172/JCI117726PubMed CentralView ArticlePubMed
  39. Benítez S, Sánchez-Quesada JL, Ribas V, Jorba O, Blanco-Vaca F, González-Sastre F, Ordóñez-Llanos J: Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction. Circulation. 2003, 108 (1): 92-6. 10.1161/01.CIR.0000072791.40232.8FView ArticlePubMed
  40. Mello AP, da Silva IT, Abdalla DS, Damasceno NR: Electronegative low-density lipoprotein: origin and impact on health and disease. Atherosclerosis. 2011, 215 (2): 257-65. 10.1016/j.atherosclerosis.2010.12.028View ArticlePubMed
  41. Lourida ES, Papathanasiou AI, Goudevenos JA, Tselepis AD: The low-density lipoprotein (LDL)-associated PAF-acetylhydrolase activity and the extent of LDL oxidation are important determinants of the autoantibody titers against oxidized LDL in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids. 2006, 75 (2): 117-26. 10.1016/j.plefa.2006.03.012View ArticlePubMed
  42. Noto H, Hara M, Karasawa K, Iso-O N, Satoh H, Togo M, Hashimoto Y, Yamada Y, Kosaka T, Kawamura M, Kimura S, Tsukamoto K: Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Arterioscler Thromb Vasc Biol. 2003, 23 (5): 829-35. 10.1161/01.ATV.0000067701.09398.18View ArticlePubMed
  43. Bazan NG: Inflammation. A signal terminator. Nature. 1995, 374 (6522): 501-2. 10.1038/374501a0View ArticlePubMed
  44. Itabe H: Oxidized phospholipids as a new landmark in atherosclerosis. Prog Lipid Res. 1998, 37 (2-3): 181-207. 10.1016/S0163-7827(98)00009-5View ArticlePubMed
  45. Steinbrecher UP, Pritchard PH: Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. J Lipid Res. 1989, 30 (3): 305-15.PubMed
  46. Frasch SC, Zemski-Berry K, Murphy RC, Borregaard N, Henson PM, Bratton DL: Lysophospholipids of different classes mobilize neutrophil secretory vesicles and induce redundant signaling through G2A. J Immunol. 2007, 178 (10): 6540-8.View ArticlePubMed
  47. Schmitz G, Ruebsaamen K: Metabolism and atherogenic disease association of lysophosphatidylcholine. Atherosclerosis. 2010, 208 (1): 10-8. 10.1016/j.atherosclerosis.2009.05.029View ArticlePubMed
  48. Quinn MT, Parthasarathy S, Steinberg D: Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA. 1988, 85: 2995-2998.
  49. Lauber K, Bohn E, Kröber SM, Xiao YJ, Blumenthal SG, Lindemann RK, Marini P, Wiedig C, Zobywalski A, Baksh S, Xu Y, Autenrieth IB, Schulze-Osthoff K, Belka C, Stuhler G, Wesselborg S: Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell. 2003, 113 (6): 717-30. 10.1016/S0092-8674(03)00422-7View ArticlePubMed
  50. Müller J, Petković M, Schiller J, Arnold K, Reichl S, Arnhold J: Effects of lysophospholipids on the generation of reactive oxygen species by fMLP- and PMA-stimulated human neutrophils. Luminescence. 2002, 17 (3): 141-9. 10.1002/bio.681View ArticlePubMed
  51. Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, Lerman A: Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation. 2007, 115 (21): 2715-21. 10.1161/CIRCULATIONAHA.106.671420View ArticlePubMed
  52. Herrmann J, Mannheim D, Wohlert C, Versari D, Meyer FB, McConnell JP, Gössl M, Lerman LO, Lerman A: Expression of lipoprotein-associated phospholipase A(2) in carotid artery plaques predicts long-term cardiac outcome. Eur Heart J. 2009, 30 (23): 2930-8. 10.1093/eurheartj/ehp309PubMed CentralView ArticlePubMed
  53. Kuniyasu A, Tokunaga M, Yamamoto T, Inoue S, Obama K, Kawahara K, Nakayama H: Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression through reactive oxygen species generation and ERK1/2 activation in 3T3-L1 adipocytes. Biochim Biophys Acta. 2011, 1811 (3): 153-62.View ArticlePubMed
  54. Vickers KC, Castro-Chavez F, Morrisett JD: Lyso-phosphatidylcholine induces osteogenic gene expression and phenotype in vascular smooth muscle cells. Atherosclerosis. 2010, 211 (1): 122-9. 10.1016/j.atherosclerosis.2010.04.005PubMed CentralView ArticlePubMed
  55. Campo S, Sardo MA, Bitto A, Bonaiuto A, Trimarchi G, Bonaiuto M, Castaldo M, Saitta C, Cristadoro S, Saitta A: Platelet-activating factor acetylhydrolase is not associated with carotid intima-media thickness in hypercholesterolemic Sicilian individuals. Clin Chem. 2004, 50 (11): 2077-82. 10.1373/clinchem.2004.036863View ArticlePubMed
  56. Tsimihodimos V, Karabina SP, Tambaki AP, Bairaktari E, Goudevenos JA, Chapman MJ, Elisaf M, Tselepis AD: Atorvastatin Preferentially Reduces LDL-Associated Platelet-Activating Factor Acetylhydrolase Activity in Dyslipidemias of Type IIA and Type IIB. Arterioscler Thromb Vasc Biol. 2002, 22: 306-311. 10.1161/hq0202.102918View ArticlePubMed
  57. Eisaf M, Tselepis AD: Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis. Biochem Pharmacol. 2003, 66 (11): 2069-73. 10.1016/S0006-2952(03)00559-8View ArticlePubMed
  58. Theilmeier G, De Geest B, Van Veldhoven PP, Stengel D, Michiels C, Lox M, Landeloos M, Chapman MJ, Ninio E, Collen D, Himpens B, Holvoet P: HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice. FASEB J. 2000, 14 (13): 2032-9. 10.1096/fj.99-1029comView ArticlePubMed
  59. Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD: PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin. Nephrol Dial Transplant. 2006, 21 (5): 1270-7. 10.1093/ndt/gfk043View ArticlePubMed
  60. Lagos KG, Filippatos TD, Tsimihodimos V, Gazi IF, Rizos C, Tselepis AD, Mikhailidis DP, Elisaf MS: Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids. 2009, 44 (1): 9-16. 10.1007/s11745-008-3251-9View ArticlePubMed
  61. Noto H, Chitkara P, Raskin P: The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes. J Diabetes Complications. 2006, 20 (6): 343-8. 10.1016/j.jdiacomp.2006.07.004View ArticlePubMed
  62. Allison MA, Denenberg JO, Nelson JJ, Natarajan L, Criqui MH: The association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients. J Vasc Surg. 2007, 46 (3): 500-6. 10.1016/j.jvs.2007.04.038PubMed CentralView ArticlePubMed
  63. Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, Wiedermann CJ, Oberthaler S, Xu Q, Witztum JL, Tsimikas S: Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007, 27 (8): 1788-95. 10.1161/ATVBAHA.107.145805View ArticlePubMed
  64. Persson M, Nilsson J, Nelson J, Hedblad B, Berglund G: The epidemiology of Lp-PLA2: Distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis. 2007, 190: 388-396. 10.1016/j.atherosclerosis.2006.02.016View ArticlePubMed
  65. Jenny NS, Solomon C, Cushman M, Tracy RP, Nelson JJ, Psaty BM, Furberg CD: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study. Atherosclerosis. 2010, 209 (2): 528-32. 10.1016/j.atherosclerosis.2009.09.021PubMed CentralView ArticlePubMed
  66. The Lp-PLA2 Studies Collaboration: Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010, 375: 1536-44.PubMed CentralView Article
  67. Tsironis LD, Katsouras CS, Lourida ES, Mitsios JV, Goudevenos J, Elisaf M, Tselepis AD: Reduced PAF-acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease. Atherosclerosis. 2004, 177 (1): 193-201. 10.1016/j.atherosclerosis.2004.07.030View ArticlePubMed
  68. Guerra R, Zhao B, Mooser V, Stafforini D, Johnston JM, Cohen JC: Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. J Lipid Res. 1997, 38 (11): 2281-8.PubMed
  69. Tsimihodimos V, Kakafika A, Tambaki AP, Bairaktari E, Chapman MJ, Elisaf M, Tselepis AD: Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res. 2003, 44: 927-934. 10.1194/jlr.M200452-JLR200View ArticlePubMed
  70. Schaefer EJ, McNamara JR, Asztalos BF, Tayler T, Daly JA, Gleason JL, Seman LJ, Ferrari A, Rubenstein JJ: Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol. 2005, 95 (9): 1025-32. 10.1016/j.amjcard.2005.01.023View ArticlePubMed
  71. Zhang B, Fan P, Shimoji E, Itabe H, Miura S, Uehara Y, Matsunaga A, Saku K: Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration. Atherosclerosis. 2006, 186 (2): 291-301. 10.1016/j.atherosclerosis.2005.07.029View ArticlePubMed
  72. O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald E: Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation. 2006, 113 (14): 1745-52. 10.1161/CIRCULATIONAHA.105.612630View ArticlePubMed
  73. Robins SJ, Collins D, Nelson JJ, Bloomfield HE, Asztalos BF: Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol. 2008, 28 (6): 1172-8. 10.1161/ATVBAHA.107.160739View ArticlePubMed
  74. Serruys PW, García-García HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Bøtker HE, von Birgelen C, D'Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A, : Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008, 118 (11): 1172-82. 10.1161/CIRCULATIONAHA.108.771899View ArticlePubMed
  75. Mohler ER, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A, : The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008, 51 (17): 1632-41. 10.1016/j.jacc.2007.11.079View ArticlePubMed
  76. Filippatos TD, Gazi IF, Liberopoulos EN, Athyros VG, Elisaf MS, Tselepis AD, Kiortsis DN: The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis. 2007, 193 (2): 428-37. 10.1016/j.atherosclerosis.2006.07.010View ArticlePubMed
  77. Spirou A, Rizos E, Liberopoulos EN, Kolaitis N, Achimastos A, Tselepis AD, Elisaf M: Effect of barnidipine on blood pressure and serum metabolic parameters in patients with essential hypertension: a pilot study. J Cardiovasc Pharmacol Ther. 2006, 11 (4): 256-61. 10.1177/1074248406296108View ArticlePubMed
  78. Rizos EC, Spyrou A, Liberopoulos EN, Papavasiliou EC, Saougos V, Tselepis AD, Elisaf M: Effects of eprosartan on serum metabolic parameters in patients with essential hypertension. Open Cardiovasc Med J. 2007, 1: 22-6.PubMed CentralView ArticlePubMed
  79. Pedersen MW, Koenig W, Christensen JH, Schmidt EB: The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults. Eur J Nutr. 2009, 48 (1): 1-5. 10.1007/s00394-008-0758-zView ArticlePubMed
  80. Kaur HD, Bansal MP: Studies on HDL associated enzymes under experimental hypercholesterolemia: possible modulation on selenium supplementation. Lipids Health Dis. 2009, 8: 55- 10.1186/1476-511X-8-55PubMed CentralView ArticlePubMed
  81. Hatoum IJ, Nelson JJ, Cook NR, Hu FB, Rimm EB: Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease. Am J Clin Nutr. 2010, 91: 786-93. 10.3945/ajcn.2009.28870PubMed CentralView ArticlePubMed
  82. Tzotzas T, Filippatos TD, Triantos A, Bruckert E, Tselepis AD, Kiortsis DN: Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women. Nutr Metab Cardiovasc Dis. 2008, 18 (7): 477-82. 10.1016/j.numecd.2007.04.004View ArticlePubMed
  83. Silva IT, Timm AS, Damasceno NRT: Lp-PLA2 as an important biomarker of cardiovascular risk in obese adolescents. Eur J Clin Nutr. in evaluation.
  84. Chen CW, Lin CT, Lin YL, Lin TK, Lin CL: Taiwanese female vegetarians have lower lipoprotein-associated phospholipase A2 compared with omnivores. Yonsei Med J. 2011, 52 (1): 13-9. 10.3349/ymj.2011.52.1.13PubMed CentralView ArticlePubMed

Copyright

© Silva et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.